Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 1 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
NICE TA1189
DostarlimabOptimised26 Aug 2026Current
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)
NICE TA1188
—Terminated (no company submission)25 Aug 2026Current
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia (terminated evaluation)
NICE TA1187
RilzabrutinibTerminated (no company submission)20 Aug 2026Current
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
NICE TA1186
Lisocabtagene maraleucelTerminated (no company submission)20 Aug 2026Current
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia
NICE TA1185
AcalabrutinibOptimised19 Aug 2026Current
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
NICE TA1184
AcalabrutinibRecommended19 Aug 2026Current
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over
NICE TA1183
DonidalorsenOptimised19 Aug 2026Current
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
NICE TA1182
FinerenoneRecommended5 Aug 2026Current
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
NICE TA1181
AficamtenOptimised30 Jul 2026Current
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
NICE TA1180
—Terminated (no company submission)16 Jul 2026Current
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
NICE TA1179
—Terminated (no company submission)16 Jul 2026Current
Deuruxolitinib for treating severe alopecia areata
NICE TA1178
DeuruxolitinibRecommended15 Jul 2026Current
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
NICE TA1177
PembrolizumabRecommended14 Jul 2026Current
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
NICE TA1176
TeplizumabRecommended9 Jul 2026Current
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis
NICE TA1175
—Optimised9 Jul 2026Current
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
NICE TA1174
CemiplimabOptimised9 Jul 2026Current
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor
NICE TA1173
PirtobrutinibOptimised1 Jul 2026Current
Atogepant for treating migraine
NICE TA1172
AtogepantOptimised30 Jun 2026Current
Seladelpar for previously treated primary biliary cholangitis
NICE TA1171
SeladelparRecommended24 Jun 2026Current
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
NICE TA1170
DaratumumabOptimised24 Jun 2026Current
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
NICE TA1169
Mirvetuximab SoravtansineRecommended24 Jun 2026Current
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)
NICE TA1168
ImlunestrantTerminated (no company submission)18 Jun 2026Current
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
NICE TA1167
SerplulimabRecommended18 Jun 2026Current
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
NICE TA1166
MepolizumabOptimised17 Jun 2026Current
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
NICE TA1165
CemiplimabOptimised16 Jun 2026Current
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment
NICE TA1164
Tisotumab VedotinRecommended11 Jun 2026Current
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)
NICE TA1163
—Terminated (no company submission)4 Jun 2026Current
Nusinersen and risdiplam for treating spinal muscular atrophy
NICE TA1162
Nusinersen, RisdiplamRecommended Optimised4 Jun 2026Current
Sotatercept for treating pulmonary arterial hypertension
NICE TA1161
SotaterceptOptimised3 Jun 2026Current
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma
NICE TA1160
DurvalumabRecommended3 Jun 2026Current
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment
NICE TA1159
Lisocabtagene maraleucelOptimised3 Jun 2026Current
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer
NICE TA1158
AmivantamabRecommended (Cancer Drugs Fund)28 May 2026Current
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over
NICE TA1157
—Optimised28 May 2026Current
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy
NICE TA1156
OsimertinibRecommended21 May 2026Current
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis
NICE TA1155
RozanolixizumabOptimised20 May 2026Current
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
NICE TA1154
OxybutyninTerminated (no company submission)7 May 2026Current
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
NICE TA1153
ZanidatamabRecommended7 May 2026Current
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
NICE TA1152
SemaglutideRecommended7 May 2026Current
Inebilizumab for treating immunoglobulin G4-related disease (terminated evaluation)
NICE TA1151
InebilizumabTerminated (no company submission)6 May 2026Current
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
NICE TA1150
EncorafenibOptimised6 May 2026Current
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma
NICE TA1149
Belantamab mafodotinOptimised30 Apr 2026Current
Sodium zirconium cyclosilicate for treating hyperkalaemia
NICE TA1148
Sodium Zirconium CyclosilicateOptimised29 Apr 2026Current
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over
NICE TA1147
VorasidenibOptimised29 Apr 2026Current
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors
NICE TA1146
RipretinibRecommended28 Apr 2026Current
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
NICE TA1145
PembrolizumabRecommended21 Apr 2026Current
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)
NICE TA1144
SpesolimabTerminated (no company submission)8 Apr 2026Current
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause
NICE TA1143
FezolinetantOptimised31 Mar 2026Current
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
NICE TA1142
DupilumabOptimised26 Mar 2026Current
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
NICE TA1141
NivolumabTerminated (no company submission)17 Mar 2026Current
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
NICE TA1140
RuxolitinibOptimised17 Mar 2026Current
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment
NICE TA1139
EpcoritamabOptimised11 Mar 2026Current
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer
NICE TA1138
DurvalumabRecommended2 Mar 2026Current
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)
NICE TA1137
CanagliflozinTerminated (no company submission)25 Feb 2026Current
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
NICE TA1136
BevacizumabOptimised25 Feb 2026Current
Baloxavir marboxil for treating and preventing influenza in people 3 weeks and over (terminated evaluation)
NICE TA1135
Baloxavir MarboxilTerminated (no company submission)19 Feb 2026Current
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps
NICE TA1134
DupilumabOptimised18 Feb 2026Current
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma
NICE TA1133
Belantamab mafodotinOptimised18 Feb 2026Current
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)
NICE TA1132
RuxolitinibTerminated (no company submission)17 Feb 2026Current
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
NICE TA1131
ObinutuzumabRecommended12 Feb 2026Current
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
NICE TA1130
TalazoparibOptimised11 Feb 2026Current
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA1129
NiraparibOptimised12 Feb 2026Current
Targeted-release budesonide for treating primary IgA nephropathy
NICE TA1128
BudesonideOptimised4 Feb 2026Current
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer
NICE TA1127
NivolumabOptimised4 Feb 2026Current
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
NICE TA1126
NatalizumabOptimised Not recommended28 Jan 2026Current
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)
NICE TA1125
PembrolizumabTerminated (no company submission)27 Jan 2026Current
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)
NICE TA1124
ConcizumabTerminated (no company submission)27 Jan 2026Current
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)
NICE TA1123
DepemokimabTerminated (no company submission)22 Jan 2026Current
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
NICE TA1122
AmivantamabRecommended21 Jan 2026Current
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy
NICE TA1121
AcoramidisRecommended14 Jan 2026Current
Avelumab with axitinib for untreated advanced renal cell carcinoma
NICE TA1120
AvelumabOptimised8 Jan 2026Current
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
NICE TA1119
VenetoclaxRecommended7 Jan 2026Current
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)
NICE TA1118
EntrectinibTerminated (no company submission)7 Jan 2026Current
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
NICE TA1117
DostarlimabOptimised16 Dec 2025Current
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
NICE TA1116
Obecabtagene autoleucelOptimised11 Dec 2025Current
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy
NICE TA1115
VutrisiranRecommended10 Dec 2025Current
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
NICE TA1114
TalquetamabRecommended3 Dec 2025Current
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA1113
GlofitamabOptimised3 Dec 2025Current
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)
NICE TA1112
Trastuzumab deruxtecanTerminated (no company submission)19 Nov 2025Current
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)
NICE TA1111
NintedanibTerminated (no company submission)19 Nov 2025Current
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer
NICE TA1110
Abiraterone acetateRecommended19 Nov 2025Current
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
NICE TA1109
DarolutamideRecommended12 Nov 2025Current
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
NICE TA1108
CemiplimabNot recommended5 Nov 2025Current
Delgocitinib for treating moderate to severe chronic hand eczema
NICE TA1107
DelgocitinibOptimised5 Nov 2025Current
Cabotegravir for preventing HIV-1 in adults and young people
NICE TA1106
CabotegravirOptimised5 Nov 2025Current
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)
NICE TA1105
—Terminated (no company submission)22 Oct 2025Current
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)
NICE TA1104
SarilumabTerminated (no company submission)22 Oct 2025Current
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
NICE TA1103
LorlatinibRecommended21 Oct 2025Current
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)
NICE TA1102
IptacopanTerminated (no company submission)29 Oct 2025Current
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over
NICE TA1101
—Optimised8 Oct 2025Current
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)
NICE TA1100
MirabegronTerminated (no company submission)1 Oct 2025Current
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy
NICE TA1099
DurvalumabRecommended1 Oct 2025Current
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable
NICE TA1098
IsatuximabRecommended24 Sep 2025Current
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable
NICE TA1097
Enfortumab VedotinRecommended11 Sep 2025Current
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
NICE TA1096
BenralizumabOptimised3 Sep 2025Current
Guselkumab for previously treated moderately to severely active Crohn's disease
NICE TA1095
GuselkumabOptimised28 Aug 2025Current
Guselkumab for treating moderately to severely active ulcerative colitis
NICE TA1094
GuselkumabOptimised28 Aug 2025Current
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over
NICE TA1093
IdebenoneRecommended28 Aug 2025Current
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
NICE TA1092
PembrolizumabRecommended27 Aug 2025Current
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments
NICE TA1091
TarlatamabNot recommended20 Aug 2025Current
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma
NICE TA1090
DurvalumabRecommended19 Aug 2025Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.